CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q4 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,695 | +0.4% | 500 | 0.0% | 0.02% | 0.0% |
| Q1 2023 | $22,615 | +11.3% | 500 | 0.0% | 0.02% | 0.0% |
| Q4 2022 | $20,325 | -38.4% | 500 | 0.0% | 0.02% | -44.4% |
| Q3 2022 | $33,000 | +10.0% | 500 | 0.0% | 0.03% | +17.4% |
| Q2 2022 | $30,000 | -3.2% | 500 | 0.0% | 0.02% | +21.1% |
| Q1 2022 | $31,000 | -18.4% | 500 | 0.0% | 0.02% | -13.6% |
| Q4 2021 | $38,000 | -32.1% | 500 | 0.0% | 0.02% | -35.3% |
| Q3 2021 | $56,000 | -30.9% | 500 | 0.0% | 0.03% | -32.0% |
| Q2 2021 | $81,000 | +575.0% | 500 | +400.0% | 0.05% | +525.0% |
| Q1 2021 | $12,000 | – | 100 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |